ncbi.nlm.nih.gov/pmc/articl...
The experts here have no doubt already read this paper, published in Feb 23. I think the work was done in France. I came across it while awake in the depths of the night! I didn't understand a lot of the scientific terms, but the general gist is clear and hopefully it will eventually help future generations of GCA/LVV patients.
"Methods: This study aimed to evaluate the effect of a novel cell therapy, Human Monocyte-derived Suppressor Cells (HuMoSC), on inflammation and vascular remodeling to improve GCA treatment. Fragments of temporal arteries (TAs) from GCA patients were cultured alone or in the presence of HuMoSCs or their supernatant. After five days, mRNA expression was measured in the TAs and proteins were measured in culture supernatant. The proliferation and migration capacity of vascular smooth muscle cells (VSMCs) were also analyzed with or without HuMoSC supernatant."
"Conclusion: Altogether, our results suggest that HuMoSCs or their supernatant could be useful to decrease vascular in flammation and remodeling in GCA, the latter being an unmet need in GCA treatment."